Merck & Co, a German multinational pharmaceutical, chemical and life sciences company, agreed to acquire Tilos Therapeutics, a privately held biopharmaceutical company developing treatment of cancer, fibrosis and autoimmune diseases, for $773m. “At Merck we continue to enhance our robust pipeline through active execution of our business development strategy," said Dr. Dean Li, senior vice president, discovery and translational medicine, Merck Research Laboratories. “Tilos has developed a compelling portfolio of candidates that employ a novel approach to modulating the potent signaling molecule TGFβ by binding to latency-associated peptide, with potential applications across a range of disease indications.”